The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis.

For the first time, a comprehensive range of potential DDIs in women of childbearing age with MS is presented. Polypharmacy is associated with the occurrence of clinically relevant DDIs. This shows the need for effective and regular screening for such interactions in order to prevent avoidable adverse effects.